# CGBIO signs $500M deal with Japan's Nippon Zoki for Novosis Putty

South Korean biopharmaceutical firm CGBIO signed an exclusive agreement worth $500 million with Japan's Nippon Zoki Pharmaceutical to develop and commercialize Novosis Putty, a bone graft treatment for lumbar spine degeneration.

- Type: Contract
- Announced: 2019-09-18
- Where: Japan
- Value: $500.0M
- Status: announced
- Products: Novosis Putty (rhBMP-2 formulation)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [CGBIO](https://endata.com/companies/42255.md)
- [Nippon Zoki Pharmaceutical](https://endata.com/companies/42257.md) (partner)

## Sources

- [cgbio.co.kr](http://www.cgbio.co.kr/en/13681), 2019-09-23: "CGBIO has entered into an exclusive agreement worth $500 million with Japan's leading firm Nippon Zoki Pharmaceutical to develop and commercialize Novosis Putty"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.